A decline in cognitive function should lead to a change in disease-modifying therapy

Abstract

Get full access to this article

View all access options for this article.

References

Sumowski

Benedict

Enzinger

et al . Cognition in multiple sclerosis: State of the field and priorities for the future. Neurology 2018; 90(6): 278–288.

Ruano

Portaccio

Goretti

et al . Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes. Mult Scler 2017; 23(9): 1258–1267.

Rocca

Amato

De Stefano

et al . Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis. Lancet Neurol 2015; 14(3): 302–317.

Weinstock-Guttman

Eckert

Benedict

RHB

. A decline in cognitive function should lead to a change in disease-modifying therapy – Yes. Mult Scler 2018; 24: 1681�1682.

Portaccio

A decline in cognitive function should lead to a change in disease-modifying therapy – No. Mult Scler 2018; 24: 1683�1684.

American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Association, 2013.

Ontaneda

Cohen

Amato

MP.

Clinical outcome measures for progressive MS trials. Mult Scler 2017; 23(12): 1627–1635.

A decline in cognitive function should lead to a change in disease-modifying therapy – Commentary

Abstract

Get full access to this article

References